New Study Finds Winning Drug for Eye Disease

Published on December 7, 2022

In the battle against age-related macular degeneration (AMD), a new study has identified a clear champion drug. Like a thrilling boxing match, the fight between the two most common drugs used to combat this eye disease has finally resulted in a decisive victory. The study, which involved 106 patients with wet AMD, revealed that aflibercept (Eylea) emerged as the undisputed winner. This means that patients treated with aflibercept had a higher success rate and were more likely to be able to reduce their reliance on medication. It’s like finding out who will reign as the champion of a karate tournament! This new research provides valuable insights into the effectiveness of different treatments for macular degeneration and could lead to improved outcomes for patients. For those looking to dive deeper into the scientific details, be sure to explore the full study!

One of the two most common drugs used to treat age-related macular degeneration (AMD) appears better than the other, a new, small study suggests. Among 106 patients with “wet” age-related macular degeneration, 50% of those treated with aflibercept (Eylea) could be weaned off…

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>